Organism: Homo sapiens
Gene: 39226_at
Selected probe(set): 206804_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39226_at (206804_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):4.29109
Number of Samples:2 / 3

Experimental	glioma study 17 (anaplastic astrocytoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):4.0422783
Number of Samples:7 / 8

Experimental	cutaneous T-cell lymphoma study 1 (plaque phase)
	Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase.
Control	normal skin tissue
	Skin biopsies from healthy individuals.

Relative Expression (log2-ratio):-3.777811
Number of Samples:5 / 29

Experimental	precursor-B-ALL study 3 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):3.737566
Number of Samples:4 / 8

Experimental	cutaneous T-cell lymphoma study 1 (tumor phase)
	Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control	normal skin tissue
	Skin biopsies from healthy individuals.

Relative Expression (log2-ratio):-3.6461554
Number of Samples:17 / 29

Experimental	precursor-B-ALL study 3 (hyperdiploid)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-3.5908403
Number of Samples:6 / 29

Experimental	precursor-B-ALL study 3 (PAX5-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-3.5907001
Number of Samples:4 / 29

Experimental	precursor-B-ALL study 3 (BCR-ABL)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-3.4248133
Number of Samples:6 / 29

Experimental	precursor-B-ALL study 3 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-3.3895683
Number of Samples:11 / 5

Experimental	kidney transplantation study 11 (1 week)
	Whole blood samples derived from kidney transplant patients 1 week post-transplantation. Samples were collected 1 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control	normal blood sample
	Blood samples derived from healthy control subjects.

Relative Expression (log2-ratio):-3.355136
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal T-cell; 20uM)
	MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---